Explore

Trendline Trendline
Diakonos Oncology's DOC1021 Receives FDA Fast Track for Melanoma Treatment

Diakonos Oncology's DOC1021 Receives FDA Fast Track for Melanoma Treatment

Diakonos Oncology's DOC1021 Receives FDA Fast Track for Melanoma Treatment
Trendline Trendline
ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients
Trendline Trendline
Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD
Trendline Trendline
Sebela Pharmaceuticals Presents Positive Phase 3 Tegoprazan Data for Erosive Esophagitis at DDW 2026

Sebela Pharmaceuticals Presents Positive Phase 3 Tegoprazan Data for Erosive Esophagitis at DDW 2026

Sebela Pharmaceuticals Presents Positive Phase 3 Tegoprazan Data for Erosive Esophagitis at DDW 2026
Trendline Trendline
FDA Rejection Highlights Challenges in Gene Therapy Approvals

FDA Rejection Highlights Challenges in Gene Therapy Approvals

FDA Rejection Highlights Challenges in Gene Therapy Approvals
Trendline Trendline
FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients

FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients

FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients
Trendline Trendline
Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions
Trendline Trendline
FDA's Rejection of Gene Therapy Highlights Evidence Challenges in Biotech

FDA's Rejection of Gene Therapy Highlights Evidence Challenges in Biotech

FDA's Rejection of Gene Therapy Highlights Evidence Challenges in Biotech
Trendline Trendline
Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat
Trendline Trendline
Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Cytokinetics' Myqorzo Achieves Success in Non-Obstructive Hypertrophic Cardiomyopathy Trial

Cytokinetics' Myqorzo Achieves Success in Non-Obstructive Hypertrophic Cardiomyopathy Trial

Cytokinetics' Myqorzo Achieves Success in Non-Obstructive Hypertrophic Cardiomyopathy Trial